

References

1. Pearle MS, et al. Medical management of kidney stones: AUA Guideline. *J Urol.* 2014;192(2):316–24. [Reviewed and validity confirmed, 2023.]
2. Cloutier J, et al. Kidney stone analysis: "Give me your stone, I will tell you who you are!" *World J Urol.* 2015;33(2):157–69. [Reviewed and validity confirmed, 2023]
3. Moe OW. Kidney stones: pathophysiology and medical management. *Lancet.* 2006;367(9507):333–44. [Reviewed and validity confirmed, 2023]
4. Qian X, et al. Epidemiological trends of urolithiasis at the global, regional, and national levels: a population-based study. *Int J Clin Pract.* 2022;2022:6807203. doi: 10.1155/2022/6807203.
5. National Kidney Foundation. Kidney stones. (www.kidney.org/atoz/content/kidneystones)

Calculi

testing at ARUP Laboratories



aruplab.com

ARUP LABORATORIES
500 Chipeta Way
Salt Lake City, UT 84108-1221
Phone: 800-522-2787
Fax: 801-583-2712


keyword: STONES

*A nonprofit enterprise of the University of
Utah and its Department of Pathology*

© 2023 ARUP Laboratories
BD-CS-025, Rev 5, December 2023



[aruplab.com/
testing/stones](http://aruplab.com/testing/stones)



ARUP offers a comprehensive menu to assess patients with kidney stone disease. **Calculi stone testing is especially effective in two areas:**

1. Assessing and monitoring the risk of stone formation (urine studies)
2. Evaluating stone composition

This testing provides valuable information to determine appropriate treatment and the course of patient care.

Epidemiology

- It is estimated that 1 in 10 individuals will develop kidney stones in their lives.
- The risk of kidney stones is around 9% in women and 11% in men in the United States.
- For those individuals who have experienced kidney stones, there is a 50% increased risk of additional development within 5 to 7 years.
- Incidence of this disease is rising and estimated to cost \$5.3 billion per year in healthcare dollars.

ARUP has designed efficient urine panels that assess stone-forming risk, monitor the course of therapy, and reduce testing expenses.

Calcium	Kidney Stone Risk Panel, Urine (0020843)	Calculi Risk Assessment, Urine (2008708)	Supersaturation Profile, Urine (2008771)		
Citric Acid					
Oxalate					
Uric Acid					
Creatinine	Calculi Risk Assessment, Urine (2008708)			Supersaturation Profile, Urine (2008771)	
Chloride					
Magnesium					
pH					
Phosphorous					
Potassium					
Sodium					
Sulfate		Supersaturation Profile, Urine (2008771)	Calculi Risk Assessment, Urine (2008708)		Supersaturation Profile, Urine (2008771)
Relative supersaturation (stone formation risk calculation):					
Calcium oxalate					
Calcium phosphate (Brushite)					
Uric acid	Supersaturation Profile, Urine (2008771)	Calculi Risk Assessment, Urine (2008708)		Supersaturation Profile, Urine (2008771)	

Benefits of Calculi Testing at ARUP

- ARUP has designed efficient urine panels that assess stone-forming risk, monitor the course of therapy, and reduce testing expenses (ARUP test codes 2008771, 2008708, 0020843).
- ARUP has developed in-house technology for stone processing, which reduces errors and decreases turnaround time.
- A full stone analysis with a photo is available through ARUP's enhanced reporting system.
- Enhanced graphical reports are available for Calculi Risk Assessment (2008708), Supersaturation Profile (2008771), and Calculi (Stone) Analysis with Photo (2005231).

Available Laboratory Testing

Test Code and Name

Evaluation of Stones	
0099460	Calculi (Stone) Analysis
2005231	Calculi (Stone) Analysis with Photo
Diagnose or Monitor Cystinuria (A Rare Genetic Disease)	
0081105	Cystinuria Panel Use to diagnose or rule out cystinuria.
0081106	Cystine Quantitative, Urine Use for monitoring treatment of patients previously diagnosed with cystinuria.
Evaluation of Stone Risk	
0020843	Kidney Stone Risk Panel, Urine
2008708	Calculi Risk Assessment, Urine
2008771	Supersaturation Profile, Urine

